ArticleJACC. Basic to translational science2019
Open access · goldAbstract read
In one paragraph
Article in JACC. Basic to translational science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 119 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
119citing papers in PubMed, 3 pooled it
12.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
119 citing papers in PubMed, 3 syntheses or guidelines pooled it, 164 citations in OpenAlex.
- Jak2 V617F clonal hematopoiesis promotes arterial thrombosis via platelet activation and cross talk.Blood · 2024Pooled it
- Clonal Hematopoiesis of Indeterminate Potential and Kidney Function Decline in the General Population.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2023Pooled it
- Association of clonal hematopoiesis mutations with clinical outcomes: A systematic review and meta-analysis.American journal of hematology · 2022Pooled it
- Coenzyme Q10 mitigates macrophage mediated inflammation in heart following myocardial infarction via the NLRP3/IL1β pathway.BMC cardiovascular disorders · 2024Trial
- Clonal hematopoiesis of indeterminate potential (CHIP), vascular somatic mutation, and cardiovascular disease: A narrative review.Vascular medicine (London, England) · 2026Review
- Targeting Thrombopoietin/MPL Signaling to Mitigate JAK2V617F-Driven Cardiac Microvascular Disease.Arteriosclerosis, thrombosis, and vascular biology · 2026Article
- Review
- Impact of CaInternational journal of molecular sciences · 2026Review
- Hematopoietic JAK2V617F mutation-induced reprogramming of blood and bone marrow megakaryocytes.Blood advances · 2026Article
- Clonal haematopoiesis and cardiovascular disease, defining risk, filling gaps, and framing the future.NPJ cardiovascular health · 2026Review
- Oridonin as a novel KDM5C inhibitor alleviates clonal hematopoiesis-induced cardiac agingActa pharmaceutica Sinica. B · 2026Article
- Inflammageing and clonal haematopoiesis interplay and their impact on human disease.Nature reviews. Molecular cell biology · 2026Review
- Targeting TPO/MPL Signaling to Mitigate JAK2V617F-driven Cardiac Microvascular Disease.bioRxiv : the preprint server for biology · 2026Article
- Clonal Hematopoiesis and Incident Heart Failure.JAMA cardiology · 2026Article
- The Immunological Consequences of Clonal Hematopoiesis in Heart Failure.Immunological reviews · 2026Review
- Clonal Hematopoiesis of Indeterminate Potential in Cardiovascular Disease: Gene-Specific Mechanisms and Therapeutic Implications.International journal of general medicine · 2026Review
- Prospective characterization of clonal hematopoiesis and its clinical associations in elderly patients.Scientific reports · 2025Article
- Clonal haematopoiesis in cardiovascular disease: prognostic role and novel therapeutic target.Nature reviews. Cardiology · 2025Review
- Immunometabolism in heart failure.Nature reviews. Cardiology · 2025Review
- Beyond Thrombosis: Pulmonary Hypertension and Heart Failure in Patients With Myeloproliferative Neoplasms: JACC: CardioOncology State-of-the-Art Review.JACC. CardioOncology · 2025Review
59 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
12 authors at 3 institutions in 2 countries.
Soichi SanoHematovascular Biology Center, Robert M. Berne Cardiovascular Research Center, University of Virginia School of Medicine, Charlottesville, Virginia.
Ying WangHematovascular Biology Center, Robert M. Berne Cardiovascular Research Center, University of Virginia School of Medicine, Charlottesville, Virginia.
Yoshimitsu YuraHematovascular Biology Center, Robert M. Berne Cardiovascular Research Center, University of Virginia School of Medicine, Charlottesville, Virginia.
Miho SanoHematovascular Biology Center, Robert M. Berne Cardiovascular Research Center, University of Virginia School of Medicine, Charlottesville, Virginia.
Kosei OshimaMolecular Cardiology, Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, Massachusetts.
Yue YangBiochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, Virginia.
Yasufumi KatanasakaDivision of Molecular Medicine, Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.
Kyung-Duk MinHematovascular Biology Center, Robert M. Berne Cardiovascular Research Center, University of Virginia School of Medicine, Charlottesville, Virginia.
Shinobu MatsuuraDepartment of Medicine and Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, Massachusetts.
Katya RavidDepartment of Medicine and Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, Massachusetts.
Golam MohiBiochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, Virginia.
Kenneth WalshHematovascular Biology Center, Robert M. Berne Cardiovascular Research Center, University of Virginia School of Medicine, Charlottesville, Virginia.
University of Virginia · USBoston University · USUniversity of Shizuoka · JP
Funding
Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Jay William FOX · 1987 to 2026
$72.1MRole of JAK2V617F in the Pathogenesis of Myeloproliferative NeoplasmsR01HL095685 · NHLBI · UPSTATE MEDICAL UNIVERSITY · PI MOHI, GOLAM · 2009 to 2018
$3.8MSomatic TET2 mutations in cardiac remodelingR01HL138014 · NHLBI · UNIVERSITY OF VIRGINIA · PI WALSH, KENNETH · 2017 to 2020
$2.6MClonal hematopoiesis and accelerated metabolic dysfunction in obesityR01HL139819 · NHLBI · UNIVERSITY OF VIRGINIA · PI WALSH, KENNETH · 2019 to 2022
$2.1MHematopoietic stem cell mutations and ischemic cardio-metabolic diseaseR01HL141256 · NHLBI · UNIVERSITY OF VIRGINIA · PI WALSH, KENNETH · 2019 to 2022
$1.9MA path to thrombosis in primary myelofibrosisR01HL136363 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI RAVID, KATYA · 2018 to 2021
$1.9MInflammatory Pathways in Aortic AneurysmsR01HL132564 · NHLBI · UNIVERSITY OF VIRGINIA · PI WALSH, KENNETH · 2016 to 2019
$1.9MThe bone marrow extracellular matrix: scaffold of hematopoiesisK01OD025290 · OD · BOSTON UNIVERSITY MEDICAL CAMPUS · PI MATSUURA, SHINOBU · 2019 to 2023
$611kNCI NIH HHS P30 CA044579NHLBI NIH HHS R01 HL095685NHLBI NIH HHS R01 HL132564NHLBI NIH HHS R01 HL136363NHLBI NIH HHS R01 HL138014NHLBI NIH HHS R01 HL139819NHLBI NIH HHS R01 HL141256NIH HHS K01 OD025290
Abstract
Janus kinase 2 (valine to phenylalanine at residue 617) (
Indexed as
AIM2, absence in melanoma 2ANOVA, analysis of varianceARCH, age-related clonal hematopoiesisBMT, bone marrow transplantCCL2, C-C motif chemokine ligand 2CHIP, clonal hematopoiesis of indeterminate potentialclonal hematopoiesisGFP, green fluorescent proteinHSC, hematopoietic stem cellHSPC, hematopoietic stem and progenitor cellIFNGR1, interferon gamma receptor 1IL, interleukinJAK2, Janus kinase 2JAK2V617F, mutant Janus kinase 2 (valine to phenylalanine at residue 617)JAK2WT, wild-type Janus kinase 2left ventricular hypertrophyLPS, lipopolysaccharideLT-HSC, long-term hematopoietic stem cellMI, myocardial infarctionMPN, myeloproliferative neoplasmmyocardial infarctionNET, neutrophil extracellular trapsSTAT, signal transducer and activator of transcriptionTAC, transverse aortic constriction surgery
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.